HK2 and breast carcinoma: As a glycolysis inhibitor, miR-143 inhibited glycolysis in breast cancer cells [42] by downregulating the expression of HK2, which is a pivotal regulator of aerobic glycolysis and tumor growth [70, 71], and the systemic delivery of miR-143 agomir inhibited tumor growth [47].